About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Apr 23, 2018...
Breast cancer cells in culture form tubelike interconnections. In this image, payloads of molecules (inside blue circles) can be seen moving along these membranous nanotubes and microtubes, illustrating how they might be transmitted to a cell in need of them. Such connections may help cancer cells share their resistance to therapeutic drugs. Ian Smith
When the physician and scientist Emil Lou was an oncology fellow at Memorial Sloan Kettering Cancer Center about a decade ago, he was regularly troubled by the sight of something small but unidentifiable in his cancer-cell cultures. Looking through the microscope, he said, he “kept finding these long, thin translucent lines,” about 50 nanometers wide and 150 to 200 microns long, extending between cells in the culture. He called on the world-class cell biologists in his building to explain these observations, but nobody was sure what they were looking at. Finally, after delving into the literature, Lou realized that the lines matched what Hans-Hermann Gerdes’ group at the University of Heidelberg had described as “nanotubular highways” or “tunneling nanotubes” (TNTs) in a 2004 paper in Science.
Mar 04, 2019...
Lymphoid organs in the small intestines. Red: B cells aggregated in the “training centers.” Green: cells with the ability to secrete effective antibodies exiting the centers for the intestinal tissue
REHOVOT, ISRAEL—March 4, 2019—Only a few vaccines – for example, polio and rotavirus – can be given orally. Most must be delivered by injection. Weizmann Institute of Science researchers suggest this may be, in part, because the “training program” of the immune cells in the gut takes place under harsh conditions. Using a novel imaging method that captures all of the immune cells’ niches within a single organ, Dr. Ziv Shulman and research student Adi Biram investigated the training process for the gut-based cells involved in long-term immunity. Their findings, published in Nature Immunology, provide new insights that may, in the future, lead to the design of more effective oral vaccines.
Apr 01, 2020...
JERUSALEM — Teams of epidemiologists and computer scientists on three continents have started mass population surveys to try to get ahead of the coronavirus and ensure that scarce diagnostic tests, and even scarcer ventilators, are sent where they can do the most good.
More than two million people in Britain and 150,000 Israelis have already completed simple questionnaires, and many are updating their answers daily. Analysts of the data — including symptoms of Covid-19 and test results, as well as risk factors and demographics — say they have been able to identify incipient outbreaks days ahead of the authorities.
May 25, 2017...
A scientist looks through a microscope. (photo credit:INGIMAGE)
Israeli startup BiomX, which is developing a treatment that selectively kills specific bacteria, last week completed a $24 million financing round. The company was founded in 2015 on the basis of research by two Weizmann Institute scientists: Dr. Eran Elinav, a specialist in microbiome – the mix of bacteria in the human body (he is also known from DayTwo, which developed an app for nutritional consultation according to a person’s individual composition of bacteria), and Professor Rotem Sorek, an expert in genetic engineering and bacterial genetics. The third founder is MIT Professor Timothy K. Lu, who specializes in genetic engineering of anti-bacterial viruses.
Mar 25, 2020... Israel is suffering a shortage of coronavirus tests, and the Weizmann Institute – working with the Ministry of Health – has transformed scientific facilities into medical facilities in order to conduct more testing. Institute leadership expects that the labs should be able to run 4,000 tests per day.
Mar 23, 2020... Dr. Nir London of the Weizmann Institute’s Department of Organic Chemistry explains his lab’s approach to fighting the coronavirus: creating a novel antiviral treatment. After identifying candidates for an antibody, he and his team are designing second-generation compounds that will go to colleagues in Germany and the U.K. for testing against the virus. Dr. London emphasizes the fact that this is open science: research that is freely available to all, for the benefit of everyone.
Oct 07, 2019...
A group of Israeli and German scientists has joined forces to defeat Ebola, one of the deadliest contagious diseases of the 21st century.A Weizmann Institute of Science lab recently started to work with a research team in Cologne, Germany, to gain a better understanding of how the vaccination against the virus affects the immune system.
“These vaccines -- made by recombinant methods that attach an Ebola protein to a harmless virus -- are hard to produce, and thus there is not enough of them to vaccinate an entire population,” explained Ron Diskin of Weizmann’s Structural Biology Department.“In addition, the civil strife in some areas where Ebola is rampant today, the facts that it is often needed in villages that are hard to reach and that because of its scarcity, the vaccine tends to be given only to those most closely connected to individuals who are already sick,” he further stated.“Understanding exactly how the immune response is produced following vaccination will not only help refine the vaccine, itself. It can help us understand whether it will work against different strains of the virus or whether the dose given today is the best one,” the scientist added. The Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.According to the World Health Organization, the Ebola fatality rate is around 50%, but it can vary from 25% to 90% in different outbreaks.
https://www.weizmann-usa.org/news-media/in-the-news/an-immune-system-trained-to-kill-cancer/
Sep 13, 2011...
CLOSE-UP Dr. Carl June examined re-engineered T-cells last week in his Philadelphia lab. Jessica Kourkounis for The New York Times
PHILADELPHIA — A year ago, when chemotherapy stopped working against his leukemia, William Ludwig signed up to be the first patient treated in a bold experiment at the University of Pennsylvania. Mr. Ludwig, then 65, a retired corrections officer from Bridgeton, N.J., felt his life draining away and thought he had nothing to lose.
Apr 12, 2018...
On April 11, 2018, American Committee supporters from across the country tuned in for CEO Marshall S. Levin's most recent conference call focused on “Science at the Leading Edge: Latest Breakthroughs from the Weizmann Institute of Science.”
As one of the deadliest flu seasons comes to a close, Mr. Levin informed the audience that Weizmann scientists have developed a universal flu vaccine that may provide full protection from all strains of the virus. The vaccine is now in late-stage clinical trials.
Jul 25, 2019...
BiondVax
A universal flu vaccine is the key to combating the ever-mutating flu virus, but did we ever really stop to think about whether there is a better way?
The flu virus, or influenza, is far more than a week-long inconvenience that pulls us away from our commitments, although that, in and of itself, is pretty annoying. The flu can get deadly fast. According to the World Health Organization, influenza kills up to 650,000 people each year. Read that number again. In the US alone, the flu kills about 12,000 people in mild years, and up to 56,000 people in the more severe years, according to the Center for Disease Control.
©2022 American Committee for the Weizmann Institute of Science
